MEDTECH

Is Deep Tech behind Australia's next resources boom?

Finfeed Archived Nov 06, 2019

According to Cicada Innovations, Australia’s next great resources boom will not be fuelled by mineral commodities but instead by research-based deep technologies.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

Next Investors Archived Oct 24, 2019

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

Why are Australians slow to adopt tech?

Finfeed Archived Oct 17, 2019

Australian employers find it significantly more challenging to train and hire staff to implement new technologies compared to their global peers.

Digital transformation provides medtech impetus

Finfeed Archived Sep 25, 2019

As we have seen with the likes of Alcidion (ASX:ALC) and Rhinomed (ASX:RNO) and BPH Energy (ASX:BPH), med tech development is crucial to the medical industry moving forward.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

Next Investors Archived Aug 14, 2019

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Next Investors Archived Jul 25, 2019

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Uscom continues to grow its position in China

Finfeed Archived Jul 24, 2019

There has been a significant growth in orders for all Uscom products in advance of the group’s China National Medical Products Administration (NMPA) applications, which are rapidly approaching approval phase.

Alcidion accorded preferred provider status in the UK

Finfeed Archived Jul 16, 2019

Shares in Alcidion Group Ltd (ASX: ALC) traded nearly 10% higher on Tuesday morning after the company announced that it had been selected in the UK as the preferred provider for Dartford and Gravesham NHS Trust’s Electronic Prescription Medications Administration System.

Medtech